IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia

Study Number

487719

Phase

I/II

Age Group

Adult

Principal Investigator

Eunice S. Wang

Purpose

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline treatment.

Check your eligibility for this trial

Check now

Full Title

A phase Ib/2 study of IMGN632 as monotherapy or combination with venetoclax and/or azacitidine for patients with CD123+ AML

ClinicalTrials.Gov ID

NCT04086264

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.